The Bioscan AN INTERNATIONAL QUARTERLY JOURNAL OF LIFE SCIENCES 20(3): S.I (3), 143-149, 2025 www.thebioscan.com

INTEGRATION OF ARTIFICIAL INTELLIGENCE AND PREDICTIVE ANALYTICS IN POST-MARKETING SURVEILLANCE SYSTEMS

CLEMENT D[1], T. SUDHEER KUMAR[1]*, R. KAMARAJ[1]

[1]Department of Pharmaceutical Regulatory Affairs, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu Dt, Tamilnadu – 603002

Corresponding Author: Dr. T. Sudheer Kumar

Corresponding Author's mail: tirumals@srmist.edu.in

Corresponding Author's Orchid ID: https://orcid.org/0009-0009-6043-8016

Mobile No: 8971055045

DOI: 10.63001/tbs.2025.v20.i03.S.I(3).pp143-149

KEYWORDS
Post Marketing Surveillance, Adverse event reporting, Machine learning technologies, Artificial Intelligence, Signal detection, Predictive analytics.
Received on:

28-05-2025

Accepted on:

29-06-2025

Published on:

01-08-2025

ABSTRACT

The continuous monitoring of pharmaceutical products and medical devices following regulatory approval represents fundamental pillar of public health protection, functioning as the principal safeguard for identifying and mitigating medication-related risks in real-world clinical settings. This comprehensive analysis investigates the contemporary landscape of post-approval safety monitoring frameworks, examining both established regulatory structures and the revolutionary impact of artificial intelligence on drug safety surveillance activities. This review digs into how different countries handle post-marketing surveillance and adverse event reporting—examining approaches from major regulators like the FDA in the US, Europe's EMA, Japan's PMDA, and other important agencies worldwide. What emerges is a mixed picture: while there's some common ground in safety monitoring practices, each region has its own unique spin on implementation. Our analysis reveals that AI technologies can significantly boost traditional PMS methods, excelling at automating signal detection, finding patterns in complex data, and catching adverse events as they happen. We're also seeing predictive analytics mature to the point where it can flag potential safety issues well before they escalate into public health crises. Looking ahead, this review charts the path forward for AI-enhanced PMS systems, examining the regulatory hurdles that need clearing, the practical challenges of getting these systems up and running, and the opportunities for creating safety monitoring that anticipates problems rather than just responding to them. Ultimately, it's about building robust systems that make a real difference in keeping patients.

INTRODUCTION

Once drugs hit the market, keeping a close eye on them becomes a critical part of the entire drug development process—it's what connects the controlled world of clinical trials to how medicines actually work in everyday life (Gandhi et al., 2025). This shift from tightly controlled studies to real-world use is a pivotal moment. That's when comprehensive safety monitoring becomes absolutely vital for protecting public health (Xu, 2023). Post-marketing surveillance serves as our main tool for catching, analyzing, and addressing side effects that might not show up until medications reach diverse patient groups in regular clinical practice (Raj et al., 2019).

Why do we need robust post-marketing surveillance? It comes down to the well-known limitations of clinical trials conducted before drug approval (Singh et al., 2023). History teaches us hard lessons—take rofecoxib's withdrawal after millions of patients faced increased heart risks. This shows why we can't stop monitoring drugs once they're approved (Yadav & Sharma, 2025). Interestingly, as predictive pharmacovigilance methods reveal, even the lack of adverse event reports tells us something important about a drug's real-world safety profile (Pitts & Le Louet, 2018).

Today's post-marketing surveillance operates through sophisticated regulatory networks spanning the globe (Afsana & Malleshwari, 2023). Major regulators—the FDA, EMA, PMDA, and others—have built comprehensive systems for tracking adverse events, spotting safety signals, and managing risks (National Medical Products Administration, 2019). These systems pull together multiple data sources: spontaneous reports from healthcare providers, regular safety updates (PSURs/PBRERs), special safety studies after approval (PASS), and risk management programs (REMS) (Central Drugs Standard Control Organization, n.d.).

But here's the challenge: modern pharmacovigilance faces an avalanche of data that keeps growing more complex (Dimitsaki et al., 2024). Consider the numbers—global adverse event databases

handle millions of reports yearly. The FDA's FAERS database holds over 20 million reports and adds 300,000 to 500,000 new ones each year (Alomar et al., 2020). WHO's VigiBase had already collected more than 20 million adverse drug reaction reports by mid-2019 (Crisafulli & Trifirò, 2025). Meanwhile, Europe's EudraVigilance houses over 16.7 million individual case safety reports, making it one of the world's largest collections (European Medicines Agency, n.d.).

Traditional pharmacovigilance methods—manual case reviews and basic statistics—simply can't keep up with this data deluge while still catching important safety signals (Alanazi et al., 2017). Think about it: clinical trials involve relatively few people over short timeframes. They can't possibly capture all the adverse effects that emerge when millions of diverse patients use medications for years (Vlahovic-Palcevski & Mentzer, 2011).

This is where AI and machine learning come in, offering game-changing possibilities for post-market surveillance (Khinvasara et al., 2024). These new technologies help automate the boring stuff, make signal detection more accurate, and catch problems before they blow up (Zinchenko et al., 2022). Natural language processing can pull useful safety information from chaotic text data and organize it properly, while machine learning finds intricate patterns that old-school statistical methods completely miss (Matheny et al., 2024).

Predictive analytics goes even further by studying past trends to anticipate future problems (Kothinti, 2024). These systems might eventually predict safety risks just by looking at a drug's molecular makeup, its properties, and early market feedback (Ghosh, 2024). Getting these tools to work in practice is tough though. You need solid validation processes, regulators on board, algorithms people can understand, and most importantly—experienced humans making the final calls on safety (Huanbutta et al., 2024).

AI-based post-market surveillance changes the whole game: instead of scrambling to fix problems, we can prevent them (Hegde, 2005). Today's systems leverage machine learning for automatic signal hunting, use deep learning to scan multiple databases simultaneously, and mix different methods to improve predictions (Kumar & Velusamy, 2025). They're uncovering connections between drugs and adverse events we never knew existed, flagging safety concerns way faster, and showing how risks differ between patient populations (Grover et al., 2023). But making this work means solving some tough problems: creating algorithms people can actually understand, satisfying regulatory requirements, maintaining data integrity, and ensuring doctors stay in the driver's seat (Alomar et al., 2020).

This detailed analysis examines the current state of post-market surveillance and its AI-driven future (Kumar et al., 2022). We break down the fundamental rules, regulations, and operational systems that govern PMS in major pharmaceutical markets (Desai & Mira Kirankumar 2024). We evaluate how we currently catch and analyze adverse events—what works, what doesn't, and what's changing in today's healthcare landscape (Kumar & Velusamy, 2025).

We also investigate how AI fits into existing pharmacovigilance workflows, looking at real applications in signal detection, pattern spotting, and predictive modeling—while keeping traditional PMS at the center (Khinvasara et al., 2019). Both time-tested methods and cutting-edge techniques get scrutinized for their actual impact on surveillance quality and patient safety (Yadav & Sharma, 2025).

To close, we outline the road ahead for AI-enhanced surveillance, considering the practical obstacles, regulatory requirements, and opportunities to create safety monitoring that's both more agile and thorough (Chen et al., 2014-2022). From start to finish, we stay focused on what really matters: keeping people safe through careful, continuous monitoring (Lenzerini, 2002).

2. Post-Marketing Surveillance

After a drug gets approved, post-marketing surveillance becomes the critical next chapter—stepping in right where clinical trials end to monitor how medicines perform in real life (Pitts & Le Louet, 2018). Why is PMS so essential? It's simple: controlled studies, no matter how thorough, just can't predict what will happen when millions of different people start taking a medication in their everyday lives (Raj et al., 2019).There's a saying in regulatory circles that really drives this home: "a drug's life truly begins after it hits the market." This captures an important truth—we only see a medication's full safety picture once it's being used widely in real clinical settings (Yadav & Sharma, 2025).

2.1. Process Flow

This figure illustrates the process flow of post-marketing surveillance.

[Fig.1. PMS Flowchart]

2.2. Need for Post Marketing Surveillance

Post-marketing surveillance serves multiple essential purposes:

- It facilitates identification of uncommon adverse events with frequencies below 1:1,000, which would necessitate impractically extensive clinical studies to detect prospectively (Khinvasara et al., 2024).
- Specific adverse reactions only become apparent when medications interact with concurrent therapies or are administered to particular patient groups not adequately represented in initial studies (Vlahovic-Palcevski & Mentzer, 2011).
- PMS delivers valuable insights regarding effectiveness compared to efficacy—evaluating drug performance in

practical clinical environments versus controlled research settings (Zinchenko et al., 2022).

The importance of PMS is demonstrated by notable historical cases of significant safety concerns discovered following approval, including cardiovascular hazards that resulted in market withdrawals despite comprehensive pre-market evaluation (Ghosh, 2024).

2.3. Objectives and Scope of Post-Marketing Surveillance

The goals of PMS transcend basic adverse event identification to include thorough safety evaluation and risk mitigation (Raj et al., 2019). Principal objectives encompass:

- Generating signals regarding potentially significant safety issues of marketed pharmaceuticals (Matheny et al., 2024).
- Collecting information to validate effectiveness in practical clinical use (Crisafulli & Trifirò, 2025).
- Determining frequencies of recognized adverse reactions and comprehending delayed or extended use effects (Gandhi et al., 2025).
- Examining potential pharmaceutical interactions (Yadav & Sharma, 2025).
- Assessing whether outcomes from specialized facilities can be reproduced in general clinical practice (Grover et al., 2023).
- Analyzing effectiveness in patient groups excluded from clinical studies (Singh et al., 2023).

Post-marketing pharmaceutical monitoring includes two interconnected disciplines: pharmacovigilance and pharmacoepidemiology (Alomar et al., 2020). Pharmacovigilance concentrates on the 'prompt identification' of 'novel' adverse drug reactions that are distinctive in their 'clinical characteristics, severity and/or frequency,' while pharmacoepidemiology encompasses the 'population-level investigation of medication utilization and associated risks' (Crisafulli & Trifirò, 2025). Combined, these fields establish the basis of contemporary PMS frameworks, facilitating both signal identification and quantitative risk evaluation (Dimitsaki et al., 2024).

3. Guidelines Available

Table .1. [Guidelines and databases for various countries]

This table outlines the guidelines and databases available for different countries.

Region / Country	Guidelines (Drugs)	Databases & Systems (Drugs)	Guideline (Medical Devices)	Databases & Systems (Medical Devices)
USA (FDA)	21 CFR Part 314 Subpart H & I- REMS Guidelines- FDA PV Guidance (505(o)(3))	FAERS (FDA Adverse Event Reporting System)- MedWatch	21 CFR Part 803 (MDR)- 21 CFR Part 822 (522 PMS studies)- Post-Approval Studies (PAS) Guidance	MAUDE (Manufacturer and User Facility Device Experience)- MedSun
EU (EMA)	GVP Modules I-XVI- Regulation (EU) 1235/2010- Directive 2010/84/EU	EudraVigilance- XEVMPD	EU MDR 2017/745 Articles 83-86- PMCF Guidance- MDCG PMS-related guidance	Eudamed (under phased implementation)- Notified Body Reports
UK (MHRA)	Retains GVP principles post-Brexit- MHRA PV Guidelines	Yellow Card Scheme	UK MDR 2002 (amended)- MHRA guidance notes	MORE (Manufacturer Online Reporting Environment)- Yellow Card for Devices
Canada (Health Canada)	PV Guidelines for Marketed Health Products- PSUR/PBRER submission guidance	Canada Vigilance Database- MedEffect	Medical Device Regulations Part 1-2- Device License Renewal & Reporting Guidelines	MDPR (Medical Device Problem Reporting System)- Health Product InfoWatch
Japan (PMDA / MHLW)	GPSP Ordinance No. 135 (2004)- GVP Ordinance- MHLW RMP Guidance	JADER (Japanese Adverse Drug Event Report database)- PMDA Gateway	- PMD Act Articles 42+- GPSP for Devices- Re-evaluation Guidance	PMDA adverse event portal- J-Medical Device Safety Network
Australia (TGA)	Australian PV Guidelines- RMP Guidelines (EU-compatible)- PBRERs	DAEN (Database of Adverse Event Notifications)- TGA eBS portal	Australian Regulatory Guidelines for Medical Devices (ARGMD)- PMS & vigilance sections	DAEN – Medical Devices- Incident Report Investigation Scheme (IRIS)
India (CDSCO / IPC)	Schedule Y- CDSCO PV Guidelines for MAHs- PvPI Guidelines	PvPI – Vigiflow- IPC AMC Network	Medical Device Rules (MDR) 2017- MvPI Guidance for Device Vigilance	MvPI Vigiflow- SUGAM portal
China (NMPA)	GVP (2021 Edition)- Risk Management Guidance- PV for MAHs (R3 format)	China ADR Monitoring Center- AE Database System	PMS Provisions under PMD Act- QMS + Re-evaluation & PMS Study Rules	NMPA Medical Device Adverse Event System

4. Current Challenges in Post-Marketing Surveillance

Although PMS frameworks have advanced internationally, substantial challenges continue to restrict their effectiveness (Gandhi et al., 2025). Under-reporting remains the biggest weakness of spontaneous reporting systems—studies show that less than 10% of serious adverse drug reactions ever get reported, and the numbers drop to just 2-4% for non-serious reactions (Alomar et al., 2020). Several factors drive this massive reporting gap: healthcare providers often don't realize they should report, they're unsure whether the drug actually caused the problem, they're pressed for time during busy clinical days, and some worry about potential legal consequences (Desai & Mira Kirankumar 2024).

Data quality constitutes another significant obstacle (Dimitsaki et al., 2024). Submissions frequently omit crucial details necessary for causality evaluation, including patient characteristics, concurrent therapies, pertinent medical background, and temporal associations (Kumar & Velusamy, 2025). Incomplete submissions restrict the capability to recognize risk factors and evaluate causality, diminishing the value of safety repositories for signal identification and risk assessment (Crisafulli & Trifirò, 2025).

The sheer explosion of data is overwhelming regulatory agencies and drug companies alike (Therapeutic Goods Administration, n.d.). Major databases now handle hundreds of thousands of reports every year, and traditional methods—where experts manually review each case—simply can't keep pace with the need for timely signal detection (Matheny et al., 2024).This information overload requires innovative methods for data processing and evaluation while preserving quality criteria for safety assessment (Khinvasara et al., 2024).

Geographic differences in PMS standards generate complexity for international pharmaceutical organizations (Ghosh, 2024). Variations in reporting schedules, required data components, and safety report formats increase administrative workload and potentially delay critical safety communications (Medicines and Healthcare products Regulatory Agency, n.d.). Although ICH harmonization initiatives have progressed, considerable differences remain in implementation across regions (Vlahovic-Palcevski & Mentzer, 2011).

5. Integration of AI in PMS

5.1. Current State of AI Adoption in Pharmacovigilance

The incorporation of artificial intelligence into pharmacovigilance signifies a fundamental transformation from reactive to anticipatory drug safety surveillance (Gandhi et al., 2025). Presently, pharmacovigilance frameworks worldwide are progressively implementing AI technologies to strengthen their abilities in identifying, evaluating, and preventing adverse drug reactions (Khinvasara et al., 2024). The utilization of AI in pharmacovigilance has progressed from theoretical concepts to functional implementations, with principal regulatory authorities spearheading this evolution (Health Canada, n.d.).

5.2. Areas Where AI is Being Implemented

5.2.1. Signal Detection and Analysis

AI adoption is moving at different paces depending on where you look (Dimitsaki et al., 2024). Big regulatory agencies are finally realizing AI might be the answer to problems that have dogged traditional pharmacovigilance for years (Matheny et al., 2024). The FDA put out new guidance stressing that we need to be careful and responsible when using AI to monitor drug and device safety (U.S. Food and Drug Administration, n.d.). Meanwhile, other heavy hitters—Europe's EMA, Japan's PMDA, and regulators worldwide—are rolling out their own programs to integrate AI into safety monitoring systems (Khinvasara et al., 2024).

Various AI tools—machine learning, deep learning, and natural language processing—are proving they can handle the heavy lifting in pharmacovigilance: catching safety signals, assessing risks, and keeping up with regulations (Singh et al., 2023). These systems really shine when dealing with mountains of chaotic data from all over—patient records, research papers, adverse event reports (Dimitsaki et al., 2024). But this move from manual to AI-assisted monitoring goes beyond just getting better tech. It's changing the entire approach to keeping medications safe on a global scale (Huanbutta et al., 2024).

Major regulatory agencies have started rolling out AI-powered systems to detect safety signals (Matheny et al., 2024). Take the Uppsala Monitoring Centre (UMC), which manages VigiBase—the world's largest collection of Individual Case Safety Reports. They've developed VigiRank, a machine learning tool that sorts through reports based on how complete they are, their clinical importance, and where they come from geographically (Gandhi et al., 2025). This smart ranking system makes global drug safety monitoring far more efficient by filtering out less relevant reports, cutting down on false alarms, and helping identify real adverse drug reactions faster (Dimitsaki et al., 2024).

The FDA launched its Sentinel Initiative back in 2008, using AI and machine learning to analyze real-world evidence from electronic health records, insurance claims, and other healthcare databases (Khinvasara et al., 2024). These AI systems can scan data from millions of patients in real-time, looking for potential adverse drug reactions. This means safety issues get flagged much faster—especially those rare but serious reactions that clinical trials might miss entirely (Matheny et al., 2024).

5.2.2. Predictive Analytics and Risk Assessment

AI makes it possible to predict which patients might have bad reactions to drugs by looking at their personal health profiles and medication history. This pinpoints the people most at risk and shows us where to concentrate our safety efforts (Kothinti, 2024). Machine learning can forecast adverse reactions by juggling many factors at once—what drug combinations someone's taking, their age and health status, their medical background—it all comes into play (Singh et al., 2023).This forward-looking approach lets healthcare providers get ahead of problems, identifying vulnerable patients before adverse events actually occur (Alanazi et al., 2017).

5.2.3. Automated Case Processing and Reporting

AI is streamlining many steps in pharmacovigilance case processing (Kumar et al., 2022). These smart systems can handle both structured and messy data from multiple sources—they catch duplicate reports, pick up on language patterns that might signal serious patient risks, and produce required documentation automatically (Dimitsaki et al., 2024). This automation takes a huge burden off human reviewers while making adverse event reporting more accurate and consistent across the board (Desai & Mira Kirankumar 2024).

5.2.4. Real-Time Monitoring Systems

AI-powered systems make it possible to monitor drug safety metrics around the clock and analyze them instantly (Khinvasara et al., 2024). These platforms never sleep—they're constantly watching incoming data streams for the earliest hints of safety problems (Ghosh, 2024). The FDA's Sentinel Initiative shows this in action: it uses AI and networked databases to keep continuous watch over medical product safety, catching potential issues the moment they start to surface (Pitts & Le Louet, 20c18).

5.2.5. Benefits of AI Integration

Bringing AI into pharmacovigilance transforms the field in several key ways:

5.2.5.1. Enhanced Efficiency and Speed: AI systems deliver dramatic improvements in how fast we can process data (Gandhi et al., 2025). While traditional signal detection methods typically need 6 to 12 months to spot new safety issues, AI-powered continuous monitoring can flag concerns the moment data comes in (Alomar et al., 2020). These systems breeze through enormous datasets and automatically prioritize cases—a huge improvement over traditional methods, where 60% of organizations find themselves drowning in data management challenges (Dimitsaki et al., 2024).

5.2.5.2. Advanced Pattern Recognition: Machine learning excels at spotting complex patterns that humans might miss entirely (Khinvasara et al., 2024). AI can detect subtle connections between drugs and adverse events, pick up on emerging safety trends faster than conventional methods, and analyze multiple data streams at once (Singh et al., 2023). This capability really shines when it comes to catching rare adverse events and drug interactions that standard statistical methods often overlook (Alanazi et al., 2017).

5.2.5.3. Regulatory Compliance Enhancement: AI serves as a regulatory watchdog, keeping track of evolving requirements and automating documentation to make audits smoother (Khinvasara et al., 2024). This cuts compliance costs—which traditionally eat up 20% of pharmacovigilance resources—while also reducing audit failures that affect 10% of organizations (Huanbutta et al., 2024).

6.Signal Detection

Pharmacovigilance uses sophisticated data analysis to catch potential safety problems (Xu, 2023). Simply put, a signal is anything that hints at a new risk or shows that a known risk is getting worse or happening more often (Matheny et al., 2024). The traditional approach relies mostly on spontaneous reporting, reviewing medical literature, and documenting cases (Gandhi et al., 2025). With spontaneous reporting—still our main method—doctors, patients, or drug companies voluntarily report side effects to databases like the FDA's FAERS or WHO's VigiBase (Alomar et al., 2020). To catch signals better, we need to sort the data into meaningful groups (by age, vaccine type, etc.), which makes it easier to see patterns emerge (Vlahovic-Palcevski & Mentzer, 2011).

6.1. Challenges in Current Signal Detection

Manual signal detection is painfully slow—it can take months to spot new safety problems, delaying critical interventions (Desai & Mira Kirankumar 2024). Sharma discovered that verifying a signal the old-fashioned way typically takes half a year to a full year (Gandhi et al., 2025). Traditional methods lean heavily on disproportionality analysis, which often misses subtle trends or emerging patterns (Dimitsaki et al., 2024). The numbers paint a grim picture: manual data entry messes up 20% of the time, different reviewers classify the same events differently 30% of the time, most organizations (60%) are drowning in data, and nearly half burn through most of their budget just on manual work (Desai & Mira Kirankumar 2024).

6.2. AI in Signal Detection

6.2.1. Machine Learning Algorithms for Signal Detection

AI catches signals by finding patterns in adverse event reports that humans would probably overlook (Dimitsaki et al., 2024). Machine learning can sift through enormous datasets and find safety problems that manual reviewers would never spot (Khinvasara et al., 2024). The E-Synthesis framework demonstrates how Bayesian approaches can predict which drugs might cause problems—essential knowledge for effective safety monitoring (Singh et al., 2023).

These smart systems can identify risky drug effects and safety trends by examining both organized data (like trial results and

health records) and messy sources (social media chatter, patient forums) (Dimitsaki et al., 2024). Machine learning excels at finding buried connections in huge data piles, often flagging critical signals way before traditional methods would catch them (Crisafulli & Trifirò, 2025).

6.2.2. Natural Language Processing Applications

Natural Language Processing (NLP) extracts useful insights from text-based sources like patient stories about side effects, revealing patterns that signal safety concerns (Matheny et al., 2024).

NLP can churn through massive amounts of text to spot drug names paired with side effects—even when patients use slang or describe symptoms in unexpected ways (Kumar et al., 2022). This lets us track drug safety through social media as it happens, giving us an extra early warning system (Desai & Mira Kirankumar 2024).

7. Comparison with Traditional Methods

Table.2. [Comparison of Traditional Pharmacovigilance vs AI enhanced Pharmacovigilance]

This table provides a comparison between the Traditional and AI enhanced Pharmacovigilance.

Traditional Pharmacovigilance	AI-enhanced Pharmacovigilance
Traditional methods face serious problems—data entry errors are common, different reviewers classify the same adverse events differently, signal detection takes too long, and the sheer volume of data becomes overwhelming (Dimitsaki et al., 2024).	AI-augmented systems enhance precision by automating data extraction and employing validation systems for real-time verification (Khinvasara et al., 2024).
Delayed Detection: 6-12 months lag in recognizing safety indicators (Desai & Mira Kirankumar 2024).	Real-Time Analysis: Instantaneous signal identification through ongoing surveillance (Khinvasara et al., 2024).
Detection Rate: Only 10-20% of adverse drug reactions identified (Alomar et al., 2020).	Predictive Analytics: Early recognition of potential concerns (Kothinti, 2024).

8. Possible Development Gateway for Signal Detection

8.1. Future Technologies and Approaches

A promising approach uses sophisticated natural language processing (NLP) to sift through mountains of unstructured data from diverse sources—social media feeds, electronic health records, and medical journals (Matheny et al., 2024). With AI's help, regulatory agencies and healthcare organizations can quickly spot emerging safety concerns, catch adverse events, and track how products perform in real-world settings (Zinchenko et al., 2022).

8.2. Predictive Analytics and Proactive Surveillance

Predictive Modeling: Machine learning can figure out which patients are likely to have bad reactions to specific drugs by looking at their health profiles and what medications they've taken before. This lets us zero in on at-risk groups and concentrate our safety efforts where they matter most (Kothinti, 2024).

AI takes predictive analytics to the next level by mixing past data with current context to see safety problems coming (Gandhi et al., 2025). With sophisticated statistical models and prediction algorithms, decision-makers can focus their attention and resources on the areas most likely to cause trouble (Ghosh, 2024). This AI-powered approach could flip the script on surveillance—instead of scrambling to respond after problems emerge, we could catch them early and prevent disasters (Alanazi et al., 2017).

8.3. Impact of AI on PMS Efficiency

Research by Soussi Tanani's team revealed just how much AI can improve adverse reaction reporting (Gandhi et al., 2025). Morocco's experience is eye-opening: once they added AI to their pharmacovigilance system, their monthly reports shot up from a measly 3.6 to 37.4 cases—that's ten times more (Alomar et al., 2020).

Case Study: IBM Watson: Multiple drug companies now rely on IBM Watson to handle their pharmacovigilance needs, letting it crunch through safety reports and flag potential issues (Khinvasara et al., 2024). Watson helps these companies and regulators catch adverse reactions way faster than humans ever could, making sure they can act quickly when new safety threats pop up (Dimitsaki et al., 2024).

8.4. Patient Safety Improvements

Hospitals and clinics are increasingly using AI that works with their electronic health records to catch risky drug combinations and side effects before they harm patients (Khinvasara et al., 2024). The payoff is clear: fewer medication mishaps and better patient outcomes (Xu, 2023).

The FDA's Sentinel Initiative shows this in action—it combines AI with networked databases to maintain round-the-clock surveillance of medical products (Zinchenko et al., 2022). This setup catches safety signals the moment they appear (Matheny et al., 2024).

8.5. Regulatory and Industry Implications

The Uppsala Monitoring Centre runs VigiBase, the biggest collection of drug safety reports on the planet, and they're leading the charge on AI adoption (Gandhi et al., 2025). Their VigiRank tool uses machine learning to sort reports by how complete they are, whether they're clinically important, and where they came from (Alomar et al., 2020).

The FDA now uses NLP to comb through patient stories and case reports in FAERS, turning signal detection into a faster, more automated process (Matheny et al., 2024).

9. Future of PMS by Integrating AI

9.1. Vision for AI-enabled Pharmacovigilance

Adding AI to pharmacovigilance could completely change how we find, track, and handle drug side effects (Gandhi et al., 2025). **Proactive Safety Management:** AI pushes us toward prevention, helping us catch and fix problems before they grow (Khinvasara et al., 2024). **Customized Pharmacovigilance Strategies:** AI makes it possible to tailor safety monitoring to each patient's unique profile and risk factors (Kothinti, 2024).

Different AI tools—machine learning, deep learning, NLP—are already proving they can handle the grunt work of pharmacovigilance: finding signals, assessing risks, and keeping up with regulations (Khinvasara et al., 2024).

9.2. Challenges in Integration of AI in PMS

The toughest part about bringing AI to pharmacovigilance is finding good data that's actually usable (Dimitsaki et al., 2024). Machine learning needs varied, trustworthy data to function properly, but getting that data is still a major headache (Singh et al., 2023). When datasets have gaps from underreporting or reflect existing biases in reporting patterns, AI systems can't perform as well as they should (Crisafulli & Trifirò, 2025).

Bias in algorithms creates another serious problem (Kothinti, 2024). AI can accidentally make existing biases worse if they're baked into the training data, producing skewed results that could hurt patients (Gandhi et al., 2025). When certain groups aren't well-represented in the data, the AI might totally miss side effects that mainly affect those populations (Dimitsaki et al., 2024).

9.3. Recommendations for Stakeholders

Getting humans and AI to work well together is key to unlocking AI's potential in pharmacovigilance (Huanbutta et al., 2024). AI should enhance human decision-making, not try to replace it (Gandhi et al., 2025). We need user-friendly AI tools that slip naturally into current workflows (Dimitsaki et al., 2024). Healthcare workers must get solid training so they can use these AI systems effectively (Khinvasara et al., 2024).

If we keep improving and learning from what's worked (and what hasn't), post-marketing surveillance can get better at catching and managing new safety problems (Raj et al., 2019). Making this work requires a well-thought-out plan: clear rules from

regulators, better transparency, and strong accountability systems (Vlahovic-Palcevski & Mentzer, 2011).

Combining AI with current pharmacovigilance systems creates both technical headaches and organizational friction (Dimitsaki et al., 2024). Most existing systems simply can't cope with the amount and complexity of data AI needs, so they'll need serious upgrades (Crisafulli & Trifirò, 2025). Plus, people who like the old ways of doing things often push back against change (Gandhi et al., 2025). Getting past this resistance means managing change carefully, explaining AI's advantages clearly, and providing thorough training (Huanbutta et al., 2024).

CONCLUSION

Adding AI and predictive analytics to post-marketing surveillance represents a major leap forward in keeping patients safe once drugs hit the market. Traditional pharmacovigilance still matters, but it's overwhelmed by the sheer size and complexity of modern safety data. This review demonstrates how AI—using machine learning, natural language processing, and instant analysis—can shift PMS from playing catch-up to staying ahead of problems. Where AI really shines is in finding signals: it spots hidden patterns and red flags that people would likely miss. These technologies do more than just find adverse events faster—they help us understand risks better across different groups of patients. But getting AI into current systems isn't easy. We have to deal with messy data, black-box algorithms, and skeptical regulators. Making it work takes teams from different fields working together with careful planning. Done right, though, AI can massively improve how we monitor drugs after approval, creating a system that's more forward-thinking, thorough, and effective. Everyone wins when healthcare can respond quickly and intelligently to keep patients safe.

REFERENCES

- Afsana M, Malleshwari GN. Post-Marketing Surveillance and Drug Safety Monitoring: Ensuring Patient Well-Being. IJTSRD. 2023;7(6):387-392.
- Alanazi, H. O., Abdullah, A. H., & Qureshi, K. N. (2017). A Critical Review for Developing Accurate and Dynamic Predictive Models Using Machine Learning Methods in Medicine and Health Care. *Journal of medical systems*, *41*(4), 69. https://doi.org/10.1007/s10916-017-0715-6
- Central Drugs Standard Control Organization (India). Pharmacovigilance Programme of India (PvPI). Available from: https://cdsco.gov.in/opencms/opencms/en/PvPI/ [Accessed June 28, 2025].
- Chen, Y.-W., Tanaka, S., Howlett, R., & Jain, L. (2016). *Innovation in medicine and healthcare 2016*. https://doi.org/10.1007/978-3-319-39687-3
- Crisafulli, S., Ciccimarra, F., Bellitto, C., Carollo, M., Carrara, E., Stagi, L., Triola, R., Capuano, A., Chiamulera, C., Moretti, U., Santoro, E., Tozzi, A. E., Recchia, G., & Trifirò, G. (2024). *Artificial intelligence for optimizing benefits and minimizing risks of pharmacological therapies: Challenges and opportunities. Frontiers in Drug Safety and Regulation, 4*. https://doi.org/10.3389/fdsfr.2024.1356405
- Desai M. K. (2024). Artificial intelligence in pharmacovigilance - Opportunities and challenges. *Perspectives in clinical research*, *15*(3), 116–121. https://doi.org/10.4103/picr.picr_290_23
- Dimitsaki, S., Natsiavas, P., & Jaulent, M. C. (2024). Applying AI to Structured Real-World Data for Pharmacovigilance Purposes: Scoping Review. *Journal of medical Internet research*, *26*, e57824. https://doi.org/10.2196/57824
- European Medicines Agency. EudraVigilance. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance [Accessed June 28, 2025].
- Ghosh, S.tran. 2024. Use of Artificial Intelligence in Medical Devices for Post-Market Surveillance. *International Journal of Scientific Research and Management (IJSRM)*. 12, 08 (Aug. 2024), 1374–1387. DOI:https://doi.org/10.18535/ijsrm/v12i08.ec05.
- Health Canada. MedEffect Canada. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html [Accessed June 28, 2025].
- Huanbutta, K., Burapapadh, K., Kraisit, P., Sriamornsak, P., Ganokratanaa, T., Suwanpitak, K., & Sangnim, T. (2024). Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, *203*, 106938. https://doi.org/10.1016/j.ejps.2024.106938
- Khinvasara, T., Tzenios, N., & Shankar, A. (2024). Post-Market Surveillance of Medical Devices Using AI. *Journal of Complementary and Alternative Medical Research*, *25*(7), 108-122. https://doi.org/10.9734/jocamr/2024/v25i7552
- Khinvasara, T., Tzenios, N., & Shankar, A. (2024). *Post-market surveillance of medical devices using AI*. *Journal of Complementary and Alternative Medical Research*, *25*, 108-122. https://doi.org/10.9734/jocamr/2024/v25i7552
- Kothinti, R. R. (2024). *Artificial intelligence in healthcare: Revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous diagnostics*. *World Journal of Advanced Research and Reviews*, *24*(3), 3394–3406. https://doi.org/10.30574/wjarr.2024.24.3.3675
- Kumar RS, Kumar RK, Krishnan GA, Prathap L. Cognitive Computational Model Using Machine Learning Algorithm in Artificial Intelligence Environment. J Pharm Neg Results. 2022;13(7):6147-54
- Kumar, R. K. S., & Velusamy, S. (2025). Harnessing Artificial Intelligence for Enhanced Pharmacovigilance: A Comprehensive Review. *Indian Journal of Pharmacy Practice*, *18*(2), 171–179. https://doi.org/10.5530/ijopp.20250145
- Lenzerini M. Data integration. Proceedings of the twenty-first ACM SIGMOD-SIGACT-SIGART symposium on principles of database systems - PODS '02. 2002.
- Lomar, M., Tawfiq, A. M., Hassan, N., & Palaian, S. (2020). Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. *Therapeutic advances in drug safety*, *11*, 2042098620938595. https://doi.org/10.1177/2042098620938595
- Matheny, M. E., Yang, J., Smith, J. C., Walsh, C. G., Al-Garadi, M. A., Davis, S. E., Marsolo, K. A., Fabbri, D., Reeves, R. R., Johnson, K. B., Dal Pan, G. J., Ball, R., & Desai, R. J. (2024). Enhancing Postmarketing Surveillance of Medical Products With Large Language Models. *JAMA network open*, *7*(8), e2428276. https://doi.org/10.1001/jamanetworkopen.2024.28276
- Medicines and Healthcare products Regulatory Agency (UK). Yellow Card Scheme - Side effects (adverse drug reactions). Available from: https://yellowcard.mhra.gov.uk/sideeffects [Accessed June 28, 2025].
- Mishra, H. P., Loriya, K., Shah, N., Grover, S., & Mishra, S. S. (2025, January 22). *Leveraging artificial intelligence to revolutionize medical device safety*. *INNOSC Theranostics and Pharmacological Sciences*. https://doi.org/10.36922/itps.6204
- N. R. Gandhi, S. K. Tuse, S. A. Patil, From Reactive to Proactive: AI-Enabled Pharmacovigilance for Improved

Patient Safety, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 3, 1877-1892. https://doi.org/10.5281/zenodo.15054932

- National Medical Products Administration (China). Provisions for Medical Device Adverse Event Monitoring and Re-evaluation. Available from: https://english.nmpa.gov.cn/2019-12/16/c_432476.htm [Accessed June 28, 2025].
- Pharmaceuticals and Medical Devices Agency (Japan). Provision of Information Regarding Post-marketing Safety. Available from: https://www.pmda.go.jp/english/safety/info-services/0001.html [Accessed June 28, 2025].
- Pitts, P. J., & Le Louet, H. (2018). Advancing Drug Safety Through Prospective Pharmacovigilance. *Therapeutic innovation & regulatory science*, *52*(4), 400–402. https://doi.org/10.1177/2168479018766887
- Raj, N., Fernandes, S., Charyulu, N. R., Dubey, A., G S, R., & Hebbar, S. (2019). Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. *Therapeutic advances in drug safety*, *10*, 2042098619865413. https://doi.org/10.1177/2042098619865413
- Singh, S., Kumar, R., Payra, S., & Singh, S. K. (2023). Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery. *Cureus*, *15*(8), e44359. https://doi.org/10.7759/cureus.44359
- Therapeutic Goods Administration (Australia). Postmarket Monitoring. Available from: https://www.tga.gov.au/how-we-regulate/tga-learn/self-paced-online-learning/university-student-educational-materials/postmarket-monitoring [Accessed June 28, 2025].
- U.S. Food and Drug Administration. Postmarketing Surveillance Programs. Available from: https://www.fda.gov/drugs/surveillance/postmarketing-surveillance-programs [Accessed June 28, 2025].
- Vlahović-Palčevski, V., & Mentzer, D. (2011). Postmarketing surveillance. *Handbook of experimental pharmacology*, *205*, 339–351. https://doi.org/10.1007/978-3-642-20195-0_17
- Xu G. The Role of Pharmacovigilance in Post-Marketing Drug Safety Monitoring. Am J Physiol Biochem Pharmacol. 2023;13(12):1-2.
- Yadav VK, Sharma SK. Transforming Pharmaceutical R&D with AI Technologies. J Pharm Qual Assur Qual Control. 2025;7(1):37-47.
- Zinchenko, V. V., Arzamasov, K. M., Chetverikov, S. F., Maltsev, A. V., Novik, V. P., Akhmad, E. S., Sharova, D. E., Andreychenko, A. E., Vladzymyrskyy, A. V., & Morozov, S. P. (2022). Methodology for Conducting Post-Marketing Surveillance of Software as a Medical Device Based on Artificial Intelligence Technologies. *Sovremennye tekhnologii v meditsine*, *14*(5), 15–23. https://doi.org/10.17691/stm2022.14.5.02